Novartis India Ltd has decided to sell its Rifampicin bulk drug business with its facility situated at Mahad, Maharashtra to Sandoz Pvt Ltd, on a going concern basis for a consideration of Rs 30.7 crore.

Novartis had informed BSE that the members of the Company have approved through postal ballot the proposal for the sale.